Synergistic interactions between 12-0-tetradecanoylphorbol-13-acetate (TPA) and imatinib in patients with chronic myeloid leukemia in blastic phase that is resistant to standard-dose imatinib

Leukemia Research

Volumn 31, Issue 10, 2007, Pages 1441-1444

  Fang, Baijun ^a   Song, Yongping ^a   Han, Zhengtao ^a   Wei, Xudong ^a   Lin, Quande ^a   Zhu, Xiaoxiu ^b   Yang, Ruyu ^c   Sun, Junzhong ^d   Tian, Guofeng ^e   Liu, Xinjian ^e   Cao, Guoshun ^b   Shi, Yin ^f   Nie, Neng ^f   Li, Dapeng ^f   Zhao, Robert Chunhua ^f  

^a Henan Tumor Hospital   (China)

^b District People's Hospital of Shangqiu   (China)

^c Central Hospital   (China)

^d People's First Hospital of Nan Yang   (China)

^e Xinhua Hospital   (China)

^f PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

12 0 Tetradecanoylphorbol 13 acetate; Blastic phase; Chronic myelogenous leukemia; Imatinib; Resistant

Indexed keywords

COLECALCIFEROL; CYTARABINE; IMATINIB; PHORBOL 13 ACETATE 12 MYRISTATE;

ADULT; ARTICLE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DYSPNEA; EVALUATION; FEMALE; FEVER; FORCED EXPIRATORY VOLUME; HEMATURIA; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PHLEBITIS; PRIORITY JOURNAL; SIDE EFFECT;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLAST CRISIS; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PIPERAZINES; PYRIMIDINES; TETRADECANOYLPHORBOL ACETATE; TREATMENT OUTCOME;

EID: 34547697373     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2007.02.004     Document Type: Article

References (8)

1. Kantarjian H., Talpaz M., O'Brien S., Garcia-Manero G., Verstovsek S., Giles F., et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukaemia. Blood 103 (2004) 2873-2878
2. Kantarjian H.M., Talpaz M., O'Brien S., Giles F., Garcia-Manero G., Faderl S., et al. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood 101 (2003) 473-475
3. Talpaz M., Silver R.T., Druker B.J., Goldman J.M., Gambacorti-Passerini C., Guilhot F., et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 99 (2002) 1928-1937
4. Han Z.T., Zhu X.X., Yang R.Y., Sun J.Z., Tian G.F., Liu X.J., et al. Effect of intravenous infusions of 12-O-tetradecanoylphorbol-13-acetate (TPA) in patients with myelocytic leukemia: preliminary studies on therapeutic efficacy and toxicity. Proc Natl Acad Sci USA 95 (1998) 5357-5361
5. Rovera G., Santoli D., and Damsky C. Human promyelocytic leukemia cells in culture differentiate into macrophage-like cells when treated with a phorbol diester. Proc Natl Acad Sci USA 76 (1979) 2779-2783
6. Koeffler H.P., Bar-Eli M., and Territo M. Phorbol diester-induced macrophage differentiation of leukemic blasts from patients with human myelogenous leukemia. J Clin Invest 66 (1980) 1101-1108
7. Graham S.M., Jorgensen H.G., Allan E., Pearson C., Alcorn M.J., Richmond L., et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 99 (2002) 319-325
8. Fang B., Zheng C., Liao L., Han Q., Sun Z., Zhao R.C., et al. Identification of human chronic myelogenous leukemia progenitor cells with hemangioblastic characteristics. Blood 105 (2005) 2733-2740